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ABSTRACT 
 
The aim of this study was to evaluate the clinical performance of an antioxidant 
(AO) gel used to treat patients suffering from drug-induced xerostomia compared to a 
placebo gel. 
The study was a double-blind, prospective, randomized clinical trial. It included 
adult subjects with drug-induced xerostomia (n=43). Unstimulated whole salivary flow 
was measured using the spit technique. A Xerostomia Visual Analog Scale (XVAS) was 
used to assess symptoms of xerostomia and a patient satisfaction survey (PSS) to 
measure satisfaction with the gel. XVAS survey evaluations were performed at baseline, 
2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks. PSS evaluations were performed at 
2 weeks, 4 weeks, 8 weeks, and 10 weeks. There was a crossover and wash out period 
from 4 to 6 weeks. Saliva was collected at each visit to measure Total Antioxidant 
Capacity (TAC). 
43 patients were randomized into two groups, active or placebo. Symptoms 
improved in the treatment group (n=21) compared to the control group (n=15) after 10 
weeks in the following PSS domains: Ability to eat, p<.05 at week 2, and Soothing 
effect, p<.05 at week 4. A significant difference was identified between the groups with 
the XVAS survey regarding  the soothing effect  after using the AO dry mouth gel 
(P<0.05). TAC analysis did not show any significant correlation with the use of gel. 
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The topical application of an antioxidant gel containing phloretin and ferulic acid 
compared to a placebo improved symptoms of drug-induced xerostomia. However, no 
significant anti-oxidant effect was found using TAC analysis. 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
 
Specific Aims 
The purpose of this study was to analyze the effect of an active anti-oxidant gel 
compared to a placebo gel on patients who complained of xerostomia, used by the same 
patients in a crossover study. Moreover, the analysis evaluated quality of life metrics and 
the objective metrics of salivary volume and total anti-oxidant capacity (TAC) within the 
two study populations. The null hypothesis was that the active gel treatment will not 
provide statistically significant additional alleviation in patient symptoms nor improve 
measurable saliva when compared to the control group.  
Saliva and Its Functions 
Whole saliva consists of a mixture of fluids from the major and minor salivary 
glands. Once excreted in the mouth, it contains crevicular fluid, food, microorganisms, 
oral epithelial cells, neutrophils, bronco-alveolar and nasal secretions.1 Major salivary 
glands include the parotid, sublingual, and submandibular glands while 400 or more 
minor salivary glands are present in most soft tissues of the oral cavity.2 The 
submandibular, sublingual and minor salivary glands primarily produce mucinous saliva 
while the two parotid glands primarily produce serous (watery) saliva. In most instances, 
unstimulated whole saliva is predominantly mucinous while stimulated salivary output is 
primarily serous from the parotid glands.  Mucinous saliva is believed to provide the 
necessary soothing lubrication needed to prevent xerostomia while deficiencies in serous 
saliva may be more suggestive of salivary gland injury and resulting reduced salivary 
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flow.3 Normal production of saliva is between 0.5 to 1.5 liters per day.4 It is composed 
of 99% water and some electrolytes such as sodium, potassium, calcium, phosphate, and 
bicarbonate. Some organic components in saliva include immuno-globulins, proteins, 
mucins, and enzymes.5 Since the organic component of protein and mucin aid with 
lubrication and coating of oral tissues, unstimulated saliva may be more protective in 
minimizing soft tissue damage in the oral cavity from microbial, chemical, and physical 
injury.6 
Saliva plays a crucial role in lubrication of the oral and oro-pharyngeal soft 
tissues as well as in speech, mastication, taste, swallowing, and digestion. It buffers an 
otherwise acidic oral environment, contains antibodies and enzymes that contribute to 
host defense, and helps in tooth remineralization. Consequently, a salivary output 
sufficient to enable a patient to benefit from its many components is essential for oral 
health. When salivary function is reduced, patients are at a higher risk for developing 
caries and periodontal diseases, as well as experiencing denture discomfort, having 
difficulty in speaking and swallowing, and for developing diseases such as candidiasis 
when compared to patients who have normal salivary flow rates.4, 7, 8  
Xerostomia 
The term xerostomia describes a clinical state in which an individual perceives 
that their mouth is dry. The term salivary hypofunction represents actual and significant 
measurable reductions in salivary flow rate. In an effort to achieve standardization, most 
researchers now use this term to denote a flow rate of 0.1 ml/min or less.9 Prevalence of 
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dry mouth and/or salivary hypofunction is nearly 100% among patients suffering from 
Sjögrens syndrome or receiving radiation for head and neck cancers.10  
Symptoms of dry mouth may worsen during nighttime because salivary flow rate 
reaches its lowest circadian levels while asleep. Moreover, snoring, sleep apnea and 
mouth breathing may worsen the symptoms.8 Consequently, performing  saliva output 
collection as nearly as possible to morning waking offers the best opportunity to 
determine minimal daily salivary flow levels.10, 11 
Xerostomia is a subjective sensation of mouth dryness and it is typically but not 
always related to salivary gland hypofunction or lower levels of normal salivary output.9 
Xerostomia has been reported to affect 1 out of every 4 or 5 adults worldwide, while 40-
60% of the older adult population between 60-80 years of age complain of xerostomia.  
Some individuals may complain of oral dryness despite having what clinically 
appears to be adequate production of saliva. However, most mouth dryness is due to 
dysfunction of the salivary glands for reasons ranging from medication-associated 
reduced salivary gland output to salivary gland destruction caused by radiation therapy, 
chemotherapy, or various systemic diseases and disorders such as Sjogren’s Syndrome, 
sarcoidosis, scleroderma, rheumatoid arthritis, lupus erythematous, diabetes mellitus, 
HIV/AIDS, and others. When studying medication associated xerostomia, it is often not 
clear whether or not oral dryness is caused by a specific disease or by the medication 
used in treatment of the disease. Social and psychological factors, including but not 
limited to depression, anxiety, and stress may also induce dry mouth.7 The prevalence of 
dry mouth,  salivary hypofunction and saliva gland damage is nearly 100% among 
  
 
 
4 
patients suffering from Sjögrens syndrome or receiving radiation for head and neck 
cancers.10  
Xerostomia in the Elderly 
It is well established that patients 65 years of age or older are at higher risk for 
developing xerostomia and salivary hypofunction, although age itself does not appear to 
cause the salivary flow reduction.3 Instead, this reduction of flow appears to be due to 
the presence of systemic diseases and disorders as well as the use of medications.12 One 
study looked closely at the elderly population living in several long-term geriatric 
facilities in France. The authors examined and queried 769 individuals and found that 
287 residents suffered from xerostomia. The incidence and severity of mouth dryness 
increased as residents aged and the use of anticholinergic medications increased. 
However,  the total number of medications taken, even xerogenic medications, did not 
result in a statistically significant reduction in salivary flow among xerostomic patients. 
The amount of medication did not appear to play a significant role. Conversely 
sialagogue medications which induced sialorrhea successfully protected against the 
harmful effects of dry mouth.13 These findings appear to attribute dryness to systemic 
factors affecting the individuals and suggest that xerogenic drugs do not necessarily 
cause salivary gland damage. 
Medication Induced Xerostomia   
To date, over 1800 drugs have been identified as being associated with mouth 
dryness, while xerostomic adverse effects have been confirmed in studies involving 
more than 400 medicaments.  Most often the causative drugs have been those used for 
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prevention or treatment of high blood pressure, anxiety, depression or other psychiatric 
conditions, hypersensitivity reactions, Parkinson’s disease, pain, and skeletal muscle 
spasm.9, 14  
Medications that have anti-sialagogue effects frequently lead to symptoms of 
xerostomia. These primarily include anticholinergic agents such as antipsychotics, 
antidepressants, diuretics, anti-hypertensives, antihistamines, sedatives and anxiolytics, 
and opioid analgesic agents as well as non-steroidal anti-inflammatory drugs. In the 
current study, subjects were considered for participation if one or more medications 
inducing xerostomia were taken for longer than a year. It is believed that medication 
induced xerostomia is not associated with destructive changes in the salivary glands.  
Therefore individuals who have a history of previous head or neck radiotherapy, 
chemotherapy or specific autoimmune diseases such as Sjogren’s Syndrome or lupus 
erythematous were excluded from the study since these conditions are known to  be 
associated with glandular damage. 15 
Saliva production may be significantly reduced due to the synergistic effect of 
multidrug therapy.14 However, this does not always seem to occur.4 As age increases, 
salivary production may be slightly reduced and is worsened if the elderly individual is 
afflicted with two or more systemic diseases and taking several types of medications that 
have been identified as potentially causing xerostomia. Recently it has been confirmed 
that some sedatives may induce relatively severe salivary hypofunction.16 
Antidepressants may also decrease salivary flow rates when compared to healthy 
subjects who are not taking antidepressants.  
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Medication Induced Salivary Gland Dysfunction 
Polypharmacy is often described as the simultaneous use of multiple drugs in a 
single individual often for the same abnormality or condition.17 It is sometimes defined 
as the simultaneous use of 4 or more drugs.18 Polypharmacy is a phenomenon most often 
seen in elderly individuals and is often the cause of xerostomia. Multidrug use may be 
the result of multiple prescriptions written by several different physicians for the same 
patient, but is often medically necessary to control single or multiple systemic disorders.  
A cross-sectional observational study of 120 elderly (>60 years old) hospitalized patients 
receiving polypharmacy confirmed an increased at risk of drug-induced xerostomia. The 
data showed that multidrug therapy may have a synergistic effect on the severity of the 
xerostomia. It was reported that using alcohol-containing antiseptic mouthwashes for 
more than two weeks worsened xerostomia in polypharmacy subjects. This finding 
affirms that oral health management can sometimes unintentionally worsen clinical 
findings and that the dental care provider must be cautious in avoiding any iatrogenic 
practices that can further lower the patient's quality of life.18  
The decrease in unstimulated salivary flow rates induced by some medications 
and by polypharmacy can be highly variable. Patients with multiple medical disorders 
requiring treatment with multiple xerostomia-inducing medications are likely to have 
more significantly reduced salivary output. Patients with salivary gland hypofunction are 
indeed more susceptible to the adverse side effects and discomfort of dry mouth 
compared to patients with normal salivary gland function.18 
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In salivary gland hypofunction cases, prescribing medications that stimulate 
salivary gland output tends to alleviate dry mouth symptoms. Parasympathomimetic 
agents such as pilocarpine or cevimeline are often used for this purpose. In most 
individuals, these medications stimulate multiple types of exocrine glands increasing 
sweat, saliva, and tear production. They have been used to improve salivary output in 
patients suffering from Sjogren’s Syndrome, Parkinson's disease, or other diseases that 
diminish salivary gland function. Sialagogues may also increase function in salivary 
glands damaged from head and neck radiotherapy. It is certainly possible that 
medication-induced salivary output may be more responsive to sialagogue therapy since 
the salivary glands are likely undamaged. As an example, a recent study evaluated 
salivary output in a group of patients taking the mild synthetic opioid, tramadol. The 
drug was shown to reduce salivary flow rates by 64 %. After administration of 
pilocarpine, salivary flow rates increased by 20% in comparison to baseline after 
Tramadol intake.  Interestingly, maximum salivary flow was increased by 147% 
compared to baseline.19  
Despite the immense data available on this topic, there has been no evidence-
based list of medications that cause xerostomic symptoms until a systematic review was 
sponsored by the World Workshop in Oral Medicine in 2015. The objective of the study 
was to organize a list of medications that induce both salivary gland dysfunction 
(MISGD) and xerostomia or subjective sialorrhea. The authors developed what they 
termed the Anatomical, Therapeutic, and Chemical Classification System.  This scheme 
first identified the organ or anatomic body systems, such as the cardiovascular and 
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musculoskeletal systems, that may require medication therapy. They then identified the 
types of pharmacological and chemical agents required to treat these systems and finally 
the specific medications in each treatment system that have been reported to cause 
xerostomia, salivary hypofunction, or sialorrhea.  Finally, they classified the level of 
evidence supporting each reported drug (See Table 1). This intense and extensive review 
offers much needed information necessary to identify drugs that may be associated with 
patient complaints of xerostomia. Those drugs with high or moderate levels of 
supportive evidence were highlighted in the list.  This classification system serves to 
confirm the effect many medications may have on salivary function.  Unfortunately, the 
influx of new drugs into the medical market potentially adds to the list of offenders, 
which have the effect but have not yet been identified. Drugs used to treat the following 
systems were often strongly associated with xerostomia or other adverse salivary effects: 
Cardiovascular, alimentary and metabolism, genitourinary and sex hormones, anti-
infective, anti-neoplastic, and immunomodulation agents, nervous system, 
musculoskeletal, sensory organs, and respiratory. The author identified 126 specific 
drugs, 56 of which showed strong evidence in regards to disruption of salivary gland 
function. These drugs fell into eight of the ten anatomical groups. Thirty-six of the drugs 
belonged in the nervous system category. Oxybutynin, tolterodine, duloxetine, 
quetiapine, bupropion, olanzapine, solifenacin, clozapine, fluoxetine,  and venlafaxine 
were the most cited in the literature.1, 12, 20  
The pathogenesis of medication-induced salivary gland dysfunction can be 
explained by their effects on the central nervous system. The initiation of salivary 
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secretion involves secretory cells that are supplied with muscarinic M1 and M3 
receptors, alpha-1 and beta-1- adrenergic receptors and peptidergic receptors. Hence, 
drugs that have antagonistic actions on these autonomic receptors may affect the 
function of salivary glands and lead to xerostomia. It is known that anti-muscarinic 
drugs trigger oral dryness by blocking parasympathetic innervation from stimulating the 
secretory cells. Moreover, it was interesting that the use of the aminobisphosphonate 
alendronate reduced the unstimulated secretion of saliva.20  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
Table 1 ACT Levels. (Wolff A, Joshi RK, Ekstrom J, et al. A Guide to Medications Inducing Salivary 
Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the 
World Workshop on Oral Medicine VI. Drugs R D 2016). 
 11 
Table 1 ACT Levels Continued. 
 12 
Table 1 ACT Levels Continued. 
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Evaluating Oral Dryness  
Three metrics involving  oral dryness have been used in clinical research. First is 
self-reported xerostomia. Since this method is primarily based on patient perception 
without guidelines to measure oral dryness, it is probably of little research value other 
than to serve as a basis for further scientific research. Secondly, reduced salivary output 
(hyposalivation) is confirmed through measurement of unstimulated whole saliva flow.  
The saliva measurement is considered positive when there is a level of unstimulated 
salivary flow that is below established norms. The median of normal unstimulated 
salivary output has been determined to be 0.3-0.4 ml. per minute while salivary 
hypofunction is identified as 0.1 ml or less of unstimulated flow per minute. Variations 
between 0.1 and 0.3 ml per minute are considered within the standard deviation of 
normal output although an unstimulated whole salivary flow rate of 0.1-0.2 ml/min is 
considered very low normal21. Thirdly, the oral cavity is clinically assessed for 
diagnostic signs and symptoms often associated with physical changes and injury 
occurring in individuals with clinically assessed dry mouth. This method is also 
problematic since these diagnostic signs and symptoms associated with xerostomia may 
be the result of some other factor resulting in false positives. Available evidence 
indicates that measurements of unstimulated or stimulated salivary output or both,  
constitute the most accurate method now available to assess salivary output.7   
Dry mouth symptoms can range from mild oral discomfort to severe oral diseases that 
compromise patients’ well-being, food consumption, and quality of life.9 Only limited 
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data is available regarding the prevalence of xerostomia in the U.S. population and 
estimates range widely from 0.9% to 64.8%.10  
Unstimulated whole saliva often is collected by means of the draining or drooling 
method, in which a patient’s head is tilted forward and pooled saliva is drooled into a 
sterile container. An unstimulated rate of 0.1ml/minute or less is suggestive of salivary 
hypofunction. A more recent study defined unstimulated hyposalivation as being less 
than a range of 0.1-0.2 ml/min.22 However, use of this range appears confusing and 
could result in inconsistent study findings. Consequently, we have elected to continue 
with the definition of hyposalivation as representing an unstimulated salivary flow rate 
of 0.1 ml. per minute or less. 
Stimulated whole saliva is collected by challenging the salivary glands to 
produce maximum output through mastication. An inert material such as paraffin wax is 
chewed and salivary flow rates are measured. Gustatory stimulation is accomplished by 
stimulating salivary gland output with a sialagogue such as citric acid. Following 
salivary gland stimulation, the patient expectorates into a collection tube. Stimulated 
whole salivary flow rates 0.7 ml/minute or below have been suggested to be consistent 
with salivary hypofunction. Patients suffering from hyposalivation tend to experience 
inadequate bicarbonate and urea buffering, tooth erosion, and decreased 
remineralization, any of which can lead to an increased dental caries rate.3, 21 
Clinically Assessed Dry Mouth 
Patients may suffer from xerostomia with or without hyposalivation, or may 
experience hyposalivation with or without symptoms of xerostomia. Therefore, 
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including a clinical assessment of oral dryness is an important component in oral care for 
these patients. One study suggests that measuring unstimulated salivary flow rates in 
older adults may or may not confirm salivary gland hypofunction even in those who 
complain of xerostomia and in those whose oral examination findings are suggestive of 
dry mouth.7   
Diagnosis of Xerostomia 
Patient Surveys: Several authorities have affirmed that asking only a few 
questions is beneficial in confirming a clinical diagnosis of xerostomia.11, 23 
Recommended questions to ask the patient include: 
 Does the amount of saliva in your mouth seem to be too little?23 
 Does your mouth feel distinctly dry?24  
 Does your mouth feel dry when eating a meal? 25 
 Do you sip liquids to aid in swallowing dry food?25 
 Do you have difficulty swallowing?26   
 Do you have dry lips?26  
 Do you have difficulty speaking?26  
 Do you have difficulty eating dry foods?26  
These questions appear to primarily assess the sensation of oral dryness.  They 
may well facilitate the diagnosis of xerostomia, but they are subjective in nature and 
responses may be influenced by level of understanding and personality of the persons 
being queried. Others have suggested that a more detailed questionnaire and evaluation 
system may more accurately measure the degree of hypofunction.23 It is not yet clear that 
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these questions are of benefit in assessing treatment outcomes for afflicted patients. A 
clinical oral examination should be conducted to assess the oral soft tissues for evidence 
of the physical changes associated with oral dryness to include the presence of 
periodontal diseases and increased incidence of dental caries. 
A thorough head and neck examination should be completed to assess the major 
salivary glands for enlargement, tenderness, or masses. The healthcare provider should 
palpate and “milk” the salivary glands while examining the intraoral salivary ducts to 
determine if they are capable of producing an adequate amount of saliva.15 
If there is suspicion of an underlying systemic condition associated with mouth 
dryness, blood studies may be beneficial in establishing the underlying etiology. Referral 
to a rheumatologist or other medical specialist is indicated if Sjogren’s Syndrome, 
rheumatoid arthritis, or various other autoimmune diseases are suspected, or glandular 
disfigurement is identified.27                     
            A complete blood count may be requested especially if an infectious process is 
suspected, and hemoglobin A1C or other serum glucose tests may be appropriate for a 
patient who is believed to be a potentially undiagnosed or inadequately controlled 
diabetic.15 
           Minor salivary gland biopsy is a useful diagnostic tool for identifying underlying 
pathological changes associated with salivary gland dysfunction, especially when the 
clinician is attempting to identify the underlying etiology of salivary dysfunction as it 
relates to systemic diseases.9,23,24 
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Current Management of Xerostomia 
Treatment planning to relieve patients from dry-mouth should be tailored to the 
individual patient. A multidisciplinary model of care for xerostomia and salivary gland 
hypofunction should include the following components: (1) patient education—a patient-
centered process emphasizing daily oral hygiene, regular dental visits, use of topical 
fluoride, tobacco-use cessation counseling, avoiding caffeine products, dietary 
modifications, and other interventions; (2) management of systemic conditions and 
medications used in consultation with the patient’s physician, oncologist, or other health 
care providers; (3) preventive measures to reduce oral disease and associated 
complications; (4) pharmacological treatment with salivary stimulants (sialagogues) and 
substitutes; and (5) for patients who cannot tolerate sialagogues, palliative measures to 
improve salivary output, such as use of sugar-free salivary stimulants like a chewing 
gum, mints, lozenges, raw carrots, celery and possibly capsaicin products.9 
Oxidative Stress in Oral Health 
Several research studies have explored the role of normal saliva in maintaining 
healthy teeth and oral soft tissues. An important aspect of this research is the correlation 
between inflammation, oxidative stress markers, and the total anti-oxidant capacity 
(TAC) of saliva. It is now known that inflammation and oxidative stress begins with a 
proliferation of free radicals including reactive oxygen species (ROS). Free radicals are 
uncharged molecules that are typically highly reactive and short-lived. They have an 
unpaired valence electron and so they attempt to “rob” electrons from other molecules. 
Unchecked, the process of “electron theft” can result in deterioration of cell walls and 
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ultimately cell or tissue damage. It has been found that in the oral cavity free radicals 
tend to result from external sources, such as alcohol, nicotine, and hydrogen peroxide, as 
well as from performance of various dental procedures and placement of a variety of 
dental materials, including veneers, implants, and crowns. Oral infections due to 
gingivitis, periodontitis or even root caries also generate free radicals as part of the 
inflammatory response.28  
           An excess of ROS or free radicals leads to oxidative stress. Prolonged oxidative 
stress can result in the development of a chronic inflammatory state including systemic 
inflammatory disease.29 However, oxidative stress can be reversed when free radicals are 
neutralized by anti-oxidant (AOs). These large, complex molecules work to stop the 
damage that free radicals start by “donating” electrons to free radicals. Each type of 
antioxidant works either by halting the electron theft or by stopping the entire process. 
Normal saliva is rich in AOs, including uric acid, albumin, ascorbic acid, 
glutathione, and specific AO enzymes.  When patients experience dry mouth, they are 
generally producing reduced quantities of saliva leading to low levels of AOs. When AO 
levels in saliva are too low to neutralize the free radicals, the tissues are prone to 
oxidative stress. In fact, several studies have implicated high levels of oxidative stress 
markers30 and low levels of salivary AOs (measured by total antioxidant capacity) in oral 
diseases including periodontal disease, aphthous ulcers, dental caries, and oral cancer.31-
35  
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Research Supporting the Positive Effects of Anti-oxidants 
AOs are important factors in minimizing the effects of free radicals and oxidative 
stress in the oral cavity. Published literature supports the topical use of polyphenols in 
the oral cavity to amplify the TAC of saliva and reduce oral oxidative stress.36 
Polyphenols are reactive metabolites found in plant-derived foods, particularly fruits, 
seeds, and leaves. Polyphenols have a chemical structure enabling them to attach to oral 
epithelial cells in a manner that results in a “time release” effect in the mouth allowing 
the polyphenols to work in concert with salivary AOs to significantly reduce oxidative 
stress in the oral cavity.36 The polyphenolic AOs, phloretin and ferulic acid, mitigate the 
adverse effects on oral fibroblasts caused by ROS from nicotine, alcohol, hydrogen 
peroxide, and other sources37. Moreover, carefully controlled mixtures of bioactive AOs 
have promoted the proliferation and migration of human oral fibroblasts.28 
Epidemiological human studies, animal studies, and in vitro studies have shown 
evidence that directly and indirectly support the importance of the presence of 
polyphenols in prevention of oral cancer.38 It has also been shown that polyphenols 
inactivate periodontal pathogens and increase AO capacity of oral fluids (saliva and 
crevicular fluid), thereby suggesting a protective effect against most periodontal 
diseases.39 There is also growing evidence to indicate that AOs may benefit individuals 
with xerostomia or salivary hypofunction.40, 41 
Xerostomia and Oxidative Stress 
Oxidative stress may be associated with some forms of xerostomia and ROS 
levels may increase as salivary hypofunction worsens. Saliva may be the first line of 
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defense against reactive oxygen species (ROS). 42 In a state of decreased salivary output, 
such as found in drug-induced xerostomia, ROS such as peroxidases flourish, which 
results in a reduction of the protective function of the saliva. Oxygen radicals mediate 
apoptosis thus causing oxidative damage to membrane lipids and proteins resulting in 
reduced function. The lack of antioxidants has been implicated in tissue damage leading 
ultimately to adverse effects associated with oral dryness.43   
One study concluded that the severe salivary hypofunction found in Sjögren’s 
Syndrome may result from lowered TAC in the salivary glands. 41 The ionizing radiation 
used in cancer treatment destroys tumors but can also cause changes in the morphology 
and function of the salivary glands and oral mucosa.44 Furthermore, an increase in ROS-
induced oxidative DNA damage has been implicated as the source of minor idiopathic 
salivary gland dysfunction found in some xerostomic patients.39  
           AOs have been used in the treatment of xerostomia caused by radiation damage to 
salivary glands. It has been found that the AO, superoxide dismutase, may protect 
salivary glands by neutralizing the superoxide ROS. 45 Another study on the 
polyphenolic AO, resveratrol, concluded that this natural AO can protect salivary glands 
from damage from direct ionizing radiation similar to that administered in cancer 
radiotherapy, and it may be effective at lessening the side effects from salivary gland 
dysfunction caused by irradiation when taken prior to the therapy.46 Polyphenols are also 
found in green tea. Epigallocatechin-3-gallate (EGCG) is the most potent green tea 
polyphenol. This polyphenol in MightTeaFlow™ lozenges was utilized in a study 
population consisting of patients with xerostomia and SS patients. After 8 weeks of 
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therapy, the formulation resulted in statistically significant increases in saliva production 
(unstimulated saliva increased 3.8 fold and stimulated saliva 2.1 fold).40 
Products for Management of Xerostomia 
There are many over-the-counter products touted to be beneficial in managing 
xerostomia and salivary dysfunction.  Although there is little evidence to support the 
benefits of many of these products, some studies have documented improved 
effectiveness in salivary output with resultant improvement in xerostomia.  A recent 
study evaluated lycopene-enriched virgin olive oil for treatment of drug-induced 
xerostomia. The oil contained the antioxidant, coenzyme Q10, which has been reported 
to increase adenosine triphosphate (ATP) production and stimulate secretory ability, and 
its use led to an increase in salivary secretion. Lycopene is a carotenoid found in 
tomatoes. This product, Surat™, was used as a spray three times a day for three-months 
in 60 patients and then compared with participants using an inert placebo. All subjects 
were taking medications that can cause hyposalivation. These drugs were classified as 
xerogenic according to the Anatomical, Therapeutic, and Chemical Classification 
System. 20, 47 The subject group was also suffering from polypharmacy-induced 
xerostomia. The authors reported an overall statistically significant increase in 
unstimulated saliva in both the treatment group and the placebo group, but the difference 
between the groups was not statistically significant. Symptoms also improved 
significantly in both groups. The reason for the improvement in both treatment and 
placebo groups was not determined. Results of this study suggested a significant increase 
of unstimulated salivary flow rate and improvement in xerostomia symptoms and 
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complaints.48  Table 2 is a modified summary of various other topical products that have 
been evaluated.22 A similar product has been studied under the name of Xerostom™ 
which contains olive oil, betaine, and xylitol and is marketed in the form of a toothpaste, 
mouth rinse, mouth spray, and gel.49 
The antioxidant gel ProVantage™ consists of ferulic acid, which is found in 
seeds and leaves of plants. Phloretin is derived from apples and polyphenolic 
antioxidants50. Polyphenolic antioxidants may provide some protection against 
xerostomia by preventing tumor necrosis factor-alpha induced cytotoxicity. They were 
mixed with a base of menthol, thymol and essential oils, sage, and clove flower oil. 
These ingredients have shown to aid in antiseptic activity51-53. The gel also included 
xylitol which supports inhibition of Streptococcus mutans.54  
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Table 2 Modified from Navarro-Morante Study-Summary of Trials on Topical Interventions. (Navarro 
Morante A, Wolff A, Bautista Mendoza GR, Lopez-Jornet P. Natural products for the management of 
xerostomia: a randomized, double-blinded, placebo-controlled clinical trial. J Oral Pathol Med 2016). 
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Table 2 Modified from Navarro-Morante Study-Summary of Trials on Topical Interventions 
Continued.  
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Validity and Reliability of Surveys 
From table 2 it is evident that many studies use Visual Analog Scales (VAS) to 
determine improvement or worsening of symptoms. Several studies have been conducted 
to prove their validity and reliability for the clinical diagnosis of xerostomia and salivary 
gland dysfunction. Visual Analog Scales (VAS) are widely used to measure pain as well. 
Most pain studies demonstrate the VAS as being valid and reliable to assess between 
chronic and experimental pain.55, 56  
There are several advantages of using a scale to represent patients’ response to 
questions asked. Investigators are able to visualize ratio properties of their responses 
Table 2 Modified from Navarro-Morante Study-Summary of Trials on Topical Interventions 
Continued. 
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which is not evident when using ordinal or categorical measurements that are 
challenging to quantify and translate. Use of a scale is beneficial in analyzing changes in 
xerostomia over time. The main study that has made use of a VAS within the field of 
xerostomia included an 8-item VAS for xerostomia. They measured unstimulated and 
stimulated saliva in 36 healthy subjects who were given an antisialogogue or placebo 
and found significant reliability for 7 of the 8 VAS items. Difficulty swallowing and lip 
dryness had a strong significant reliability whereas the amount of saliva in the mouth 
was not significant. Significant correlations were observed measuring moving averages 
for VAS and salivary flow rate values. The validity of the VAS questionnaire was 
decided by comparing baseline VAS values with the baseline salivary measurements. 
This study showed that nearly all the VAS items were significantly reliable.57 
In another study evaluating the use of a xerostomia VAS in older people who 
were residents at community care centers, investigators also found VAS to be highly 
reliable and valid. This study compared the VAS to oral health-related quality of life 
measures and found a significant association between subjective and objective dry 
mouth. It even compared the Fox questionnaire to VAS. The Fox questionnaire is 
answered using ordinal categories from rare to always. Questions were converted in a 
manner that they could be answered with a VAS. The validity of subjective dryness 
when measured with VAS instrument was high. The correlation between the scores in 
regards to the question “does your mouth feel dry?” was very significant. Over all, this 
study demonstrated that dry mouth conditions correlate with quality of life in frail 
elderly people.25, 58 
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Total Antioxidant Capacity  
The concept of Total Antioxidant Capacity (TAC) was formulated to identify all 
the cumulative effects of the antioxidants present in plasma and body fluids. It may be a 
convenient method for quantification of antioxidant effectiveness in preventing 
disease.59 Uric acid is the major antioxidant in saliva accounting for 85% of TAC of both 
stimulated and unstimulated saliva. Other naturally occurring salivary antioxidants 
include albumin, ascorbate, and glutathione. It has been claimed that unstimulated saliva 
contains higher total antioxidant capacity than stimulated samples. Consequently, since 
saliva carries so many antioxidants, it is difficult, time consuming, expensive, and 
probably unnecessary to measure AOs in both unstimulated and stimulated saliva 
independently. Therefore, TAC of unstimulated saliva could be a suitable measure of the 
antioxidant systems since AOs function together and measurement of any individual 
antioxidant may be less representative of the whole antioxidant status.60 
TAC activity in saliva is measured by the 2,2’-azinobis(3-ethylbenzothiazoline-
6-sulphonic acid) radical cation (ABTS+). This method works based on the ability of 
antioxidant molecules to quench the long-lived ABTS+, blue-green chromophore with 
characteristic absorption at 734 nm.31 The reaction is based on the ability of aqueous and 
lipid antioxidants to inhibit the oxidation of the 2,2’-azinobis(3-ethylbenzothiazoline-6-
sulphonic acid) (ABTS) to ABTS +.  ABTS+ is formed by the interaction of ABTS with 
ferrylmyoglobin radical species, generated by the activation of metmyoglobin with 
hydrogen peroxide resulting in the blue-green color. The antioxidants in the sample 
cause suppression of the absorbance of ABTS+.61 The capacity of the antioxidants to 
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prevent ABTS oxidation is then compared with that of standard Trolox, a water soluble 
tocopherol (Vitamin E) analogue via an antioxidant analysis assay kit. It is called the 
“Trolox equivalent antioxidant capacity” (TEAC) method or 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid assay.62 There are other methods to measure TAC 
as well. They include the “ferric reducing-antioxidant power” (FRAP), which is based 
on reduction of ferric ions to ferrous ions. This is done by the effect of reducing power 
of the plasma constituents measured spectrophotmetrically at 593 nm. Another TAC 
method includes the “oxygen radical absorbance capacity” (ORAC). It is based on the 
ability of plasma to trap peroxyl radicals formed from thermal decomposition of azo 
initiators and measurement of fluorescence decay of B-phycoerythrin. This study utilized 
the TEAC method due to its simplicity and reported high analytic quality.63  
Based on current literature, there appears to be strong indications that free 
oxygen radicals may play a damaging role in the development of salivary gland 
hypofunction. However, there is insufficient information about using ProVantage 
AntiOxidant™ Gel as a means of reducing oxidative stress in medication related 
xerostomic individuals and whether or not its daily use leads to any differences in 
salivary volume and TAC in patients with hyposalivation or the sensation of xerostomia 
compared to controls. There is also evidence that reduced levels of saliva are linked to 
subtle or obvious inflammation of the oral soft tissues, which may also be adversely 
influenced by free oxygen radicals. Anecdotal studies indicate that many patients find 
relief from the discomfort associated with xerostomia when treated with antioxidant 
therapy. Thus, it is the purpose of this study to evaluate the role of ProVantage AO 
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Gel™ therapy in management of medication-induced xerostomia. We propose 
evaluation of the TAC and ROS levels in patients with medication-associated xerostomia 
before and after use of ProVantage AO Gel™ as well as to assess any patient- perceived 
improvement in comfort following AO therapy compared to controls. 
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2. METHODS AND MATERIALS
This prospective cohort study was a crossover clinical trial to test the effect of a 
topically applied active antioxidant gel against a placebo in improving the quality and 
quantity of saliva as well as reducing clinical symptoms of medication-induced 
xerostomia.  Changes in salivary flow rate and patient-perceived oral health using 
various quality-of-life criteria were determined at baseline, two weeks, and four weeks 
prior to crossover period of 2 weeks and again at baseline, two, and four weeks after 
crossover (Figure 1). Patient satisfaction regarding the treatment modality was also 
evaluated. 
In this study, 45 human patients with medication-induced xerostomia were 
enrolled. For the purpose of this study, a patient with “medication-induced xerostomia” 
was defined as a patient who had been using at least one systemic medication for at least 
a year that had been reported to cause xerostomia as a side effect, and who did not have 
a history of Sjogren’s Syndrome, sarcoidosis, or head and neck radiation therapy. Upon 
enrollment, each patient completed four Patient Satisfaction Survey (PSS) and six 
Xerostomia Visual Analog Scale (XVAS) evaluations. Each participant was given a gel 
to use at home, blinded to which was the active gel or inactive placebo. At the initial 
visit, informed consent was obtained from each patient, surveys completed, saliva 
collected, and instructions were given to use the gel three (3) times per day: after their 
normal oral care regimen in the morning, mid-day after eating, and just before bed. 
  
 
 
31 
Patients returned to Texas A&M University College of Dentistry (TAMUCOD) at 2 
weeks and 4 weeks after the initial appointment for saliva sampling and completion of 
the XVAS. After 4 weeks of using the active gel or placebo, all patients stopped using 
any gel product and continued only with their normal oral care regime for a period of 2 
weeks (washout period). At the conclusion of the two-week washout period, patients 
returned to TAMUCOD to provide salivary samples and to establish a new baseline at 
week 6. At that office visit, they were given the second gel and instructed to resume the 
same usage schedule of three (3) times per day. They were asked to return to 
TAMUCOD at 8 weeks and again at 10 weeks to complete the visual analog scale 
(XVAS) and provide saliva samples (Figure 1). 
               
Figure	1	Study	Timeline	
4 weeks 8 weeks  
2 weeks 6 weeks 10 weeks 
Study Timeline 
Baseline 
XVAS, TAC 
Patient Satisfaction Survey, 
XVAS, TAC 
Patient Satisfaction Survey, 
XVAS, TAC 
Patient Satisfaction Survey, 
XVAS, TAC 
XVAS, TAC Patient Satisfaction Survey, 
XVAS, TAC 
 
 
	
The gel products were arranged in numerical order from 1 to 45 marked as either 
A or B. and randomized so that neither the patient nor investigator was able to 
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distinguish between the active gel or placebo, and the investigator did not know how 
many patients were using the active gel or placebo during the pre- or post-crossover 
period. 
Patients were assigned the number on their product series; for example each 
patient was given a specific number with an A and B component but the patient was 
known by his/her initial number, 1, 2 etc. throughout the study to ensure privacy and 
assure operator blindness.  Patients were not allowed to undergo dentist/hygienist dental 
prophylaxis, debridement, or scaling and root planing during the trial period but were 
instructed to use their own personal oral care regime. Patients were compensated $15 per 
visit for participating in the study. 
Patient Population 
Inclusion criteria for the study participants were adults ranging in age from 18 to 
85 years.  At the initial visit, the investigators provided informed consents. Once a 
patient consented to participate in the study, a xerostomia visual analog scale survey and 
patient satisfaction survey were completed to determine the baseline level of xerostomia 
per patient. Past medical and dental records were reviewed to determine probable cause 
of xerostomia.  Patients with xerostomia likely due to medication were admitted into the 
study.  During each subsequent visit patients completed the PSS and XVAS, and salivary 
flow was measured, and saliva samples were collected for total antioxidant capacity 
assay. The selection criteria included: 
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Inclusion criteria: 
•     Age: 18-85 
•     Both men and women of all ethnicities were included. 
      •     Systemic conditions: generally healthy, ASA I or II. 
 •     Has used at least one systemic medication for one or more years that had 
been reported to cause xerostomia as a side effect. 
Exclusion criteria: 
•     Current smoker or smoker within the past 10 years 
•     Pregnancy 
•     History of head and neck radiation treatment or recent chemotherapy. 
•     History of salivary impairments such as salivary stones or previous salivary 
gland surgeries due to neoplasm or sialolithiasis.  
• Allergy to any of the following ingredients: phloretin, ferulic acid, thyme, 
sage oil, clove flower oil, xylitol. 
• Presence of primary biliary cirrhosis, sarcoidosis, uncontrolled diabetes, 
HIV, Sjogren’s Syndrome. 
The Active Gel 
The active gel, labeled by PerioSciences as AO ProVantage™, contains 
compounds generally recommended as safe by the FDA, and is currently dispensed in 
dental offices along with an antioxidant-containing toothpaste and mouthwash.  The gel 
was launched as a cosmetic in 2010 after completion of a six-week safety study with 100 
patients. While the gel is extremely well tolerated and many practitioners use the gel 
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with xerostomia conditions, no medical claims have been made in marketing the AO 
ProVantage™. Anecdotal evidence provided by dentists, as well as preliminary data 
from a pilot clinical study indicate that AO ProVantage™ provides symptomatic relief 
from dry mouth that may be equal to or superior to other marketed non-prescription 
remedies. The gel is composed of glycerin 10%, water, xylitol, propylene glycol, PEG 
12, sorbitol, poloxamer 407, cellulose gum, phloretin, ferulic acid, thyme, sage oil, clove 
flower oil, potassium sorbate, menthe piperita (peppermint) leaf oil, spilanthes, acmella 
extract, sodium hyaluronate, caprylic/carpic triglyceride, sodium chloride, sodium citrate 
and disodium EDTA. 
Study Organization 
PerioSciences cotracted with TAMUCOD to provide the active gel and placebo 
gel similar in texture and taste in identical containers. The Thesis Committee conducted 
regular meetings to monitor progress, solve problems, ensure proper recruitment and 
retention of patients, ensure proper treatment protocol, address potential adverse events, 
and review data management. 
Patient Recruitment Plan 
Patients consented into the study were registered patients of the TAMUCOD 
Stomotology Center and the dental college. After discussion of the proposal and signing 
of the informed consent approved by the TAMUCOD Institutional Review Board (IRB), 
a fully executed copy of the consent document was provided to the participant and the 
original retained by the principal investigator.  
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Participating patients attended 6 clinical sessions in this crossover random 
controlled double blinded study.  At the first session, baseline xerostomia assessment 
and saliva collection was obtained and other data collected as necessary and the active or 
placebo gel was dispensed to participants. Data was again collected at two weeks 
intervals for a total of four weeks. This was followed by a two week washout period and 
the procedure was repeated for another 4 weeks using the opposite of the active or 
placebo gel previously dispensed. 
At each visit the patient was examined, a patient questionnaire completed, and saliva 
was collected to be quick frozen and subsequently used to determine variations in total 
antioxidant capacity, and salivary output. 
Measurement of TAC 
 TAC of each saliva sample was measured by antioxidant assay kit from Cayman 
Chemical. Each assay kit included a 96-well plate in which two blanks, two total 
activity, two nonspecific binding, two maximum binding, two sets of standards, and 36 
duplicate saliva samples were assayed. Saliva was diluted 1:2 with assay buffer before 
assaying. Trolox standard wells were prepared by adding 10 µl of Trolox standard, 10 µl 
of Metmyoglobin, and 150 µl of Chromogen per well. Sample wells needed 10 µl of 
sample, 10 µl Metmyoglobin, and 150 µl of Chromogen to wells. To obtain reproducible 
results, antioxidant levels of the samples should fall within the standard curve. Reaction 
was initiated by adding 40 µl of Hydrogen Peroxide Working Solution to all the wells 
being used. The covered plate was incubated for 5 minutes at room temperature. The 
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absorbance was read at 750 nm using a plate reader. The data for the standard curve was 
plotted and compared to the sample results to determine TAC levels between visits.  
Measurement of Salivary Flow 
Patients were asked to supply two saliva samples during each visit including the 
initial visit.  They were instructed to provide these samples before eating, drinking, 
brushing, or rinsing after waking. To measure the quantity of saliva, one unstimulated 
sample was collected without stimulation after a non-alcohol containing, purified water 
rinse. This was accomplished at the beginning of the visit by having the patient spit into 
a sterile container over 5 minutes. A second saliva sample was collected at the end of the 
visit using the same collection protocol to measure Total Antioxidant Capacity (TAC) in 
the saliva sample. Saliva was quick-frozen and stored and stored for future assessment. 
Gel Usage 
The gel tubes were weighed on a calibrated scale at every visit to monitor the 
usage of the gels throughout the study on a calibrated scale. These values were recorded 
to ensure compliance and measure usage amount. 
Survey Instruments 
To assess the impact on oral health-related quality of life (OHQOL) among 
xerostomia patients, the study used two different instruments. Xerostomia Visual Analog 
Scale (XVAS) were based on the work of Thomson and Patient Satisfaction Survey 
(PSS).23 The visual analog scale (VAS) evaluated the occurrence of specific symptoms, 
using a 10-point scale ranging from “Rarely” to “Always.” Subjects were asked to mark 
a vertical line through a 10cm horizontal ruler to show level of symptoms (0, rarely 
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experiencing symptoms; 10, always experiencing symptoms). The VAS was used to 
evaluate symptoms at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks.  It 
consisted of five items: (1) Difficulty in speaking; (2) difficulty in swallowing, (3) 
decrease in saliva in the mouth, (4) dry mouth, and (5) dry throat.  
 
 
   Figure 2 Xerostomia Visual Analog Scale  
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PSS measured perceived satisfaction on five aspects of the AO gel product using 
a simple five-point Likert scale, from “Very Satisfied” to “Very Unsatisfied.” Subjects 
were asked to evaluate changes to symptoms as they finished using the gel. The 
satisfaction scale asks participants to best describe how their symptoms are now 
compared to how they were before applying the gel. The questionnaire was completed  
at baseline, 2 week, 4 week, 8 week, and 10 week visits. It assessed the following five 
variables: 
1) Time it took to feel relief after using the dry mouth gel.
2) Confidence in breath after using the dry mouth gel.
3) Ability to eat after using the dry mouth gel.
4) The soothing effect in the mouth after using the dry mouth gel
5) The ability to sleep through the night after using the dry mouth gel.
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Figure 3 Patient Satisfaction Survey 
 
 
Data Collection and Analysis 
All survey data was entered and stored at TAMCOD.  All saliva specimens were 
stored frozen in an -80 degrees Celsius freezer at TAMUCOD for TAC analysis.  The 
samples were centrifuged at 1250g for 10 min at 4 degrees Celsius prior to freezing. 
Forms were organized for each patient visit. Each form had space for the following 
identifiers: patient number, patient initials, treatment type, and visit number. 
Treatment/measurement performed was recorded on the form. When a visit was 
completed, the investigators checked each form for accuracy and completeness. After 
forms had been reviewed for clinical features and checked for completeness, they were 
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logged into the database and a forms checklist for each patient updated. After logging 
the data, forms were entered into a computer, producing primary and secondary data 
files. The data entry procedure was designed to allow only codes listed on the form and 
values in the expected format to be entered. Reports were developed to list completion 
status, exits, and forms for subsequent statistical analysis. 
Confidentiality of patient data is always an important consideration. The 
biostatistician did not receive the patient’s name or any identifier such as medical record 
number or SSN. Copies of data forms were stored in a locked file cabinet in the locked 
office of the Principal Investigator. 
The software platform for the study was Microsoft ® 2000. Programs and data 
resided on a computer at TAMUCOD. The computer is located in a room with restricted 
access. In addition to passwords necessary to log into the computer and receive access to 
the database directory, security limited entry to the database to only specific users via 
password. The computer was backed up daily to an external hard drive. The study 
database was backed up to zip disk or CD periodically. The computer is protected with 
an uninterruptible power supply (ups). 
For this study, 45 patients were recruited, and using a within patient standard 
deviation of 12 ng/mL and a type I error rate of 0.05, a difference between treatments of 
24 units was considered significant. As this patient population is considered to be highly 
motivated, a 20% drop-out rate is assumed, so 45 patients were recruited for the study. 
Active gel and placebo groups were compared using Mixed Model Analysis.  Medians 
were used to describe characteristics of the patient population. 
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The primary hypothesis of the study was that the active gel would increase TAC 
in saliva compared to placebo. A linear mixed model statistical analysis was used to 
examine the outcome variable TAC.  The “between” factor was the two treatment groups 
(active gel versus placebo), while the “within” factor was the time measurements made 
(baseline, 2 week, 4 week, 6 week, 8 week, and 10 weeks). 
A linear mixed model statistical analysis was used to examine each outcome 
variable listed below.  The “between” factor was the two treatment groups (active gel 
versus placebo), while the “within” factor was the time measurements made (baseline, 2 
week, 4 week, 6 week, 8 week, and 10 weeks). The secondary hypotheses that the active 
gel provided better treatment outcomes than placebo included: (1) TAC analysis, (2) 
salivary flow rate, (3) Xerostomia Visual Analog Scale.  
Five aspects of the antioxidant gel product were assessed using a simple five-point 
Likert scale, from “Very Satisfied” to “Very Unsatisfied.” Patient responses to the 
satisfaction survey were combined into a total score. In this analysis the time 
measurements included baseline, 2 week, 4 week, 6 week, 8 week and 10 weeks. 
To analyze data, IBM SPSS V20 was utilized. All tests, unless otherwise noted, were 
performed using p < 0.05. 
Analysis strategies included performing Mixed Model Analysis. Certain models 
were used to account for the effects of missing data on the analysis. Missing data, when 
using a mixed-models approach (as MIXED in SPSS), is not problematic.  In a mixed-
models approach, the patient is considered randomly chosen from a larger group of 
subjects.  These models have been found to be tolerant of missing data as long as the 
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missing data are random. Active gel and placebo groups was compared using paired t-
test. Medians and semi-interquartile ranges were used to describe characteristics of the 
patient population when the data was continuous and non-normally distributed. 
We proposed using multivariate analysis of variance, wherever feasible, rather 
than individual analysis of covariance adjusting for Type I error rates. 
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3. RESULTS 
      
Figure 4 Study overview 
Assessed	for	eligibility	(n=45)	
Allocated	to	placebo	ﬁrst.	P-A	group	(n=18)	Allocated	to	Ac?ve	gel	ﬁrst.	A-P	group		(n=25)	
Lost	to	follow-up	(n=1)	
Reason:	started	to	smoke	again	
Lost	to	follow-up	(n=3)		
Reason:	Discon?nued	treatment	due	to	scheduling	conﬂicts		
Lost	to	follow-up	(n=1)	
Reason:	1	subjects	reported	being	diagnosed	with	inﬂuenza	
Lost	to	follow	up	(n=1)		
Reason:	1	subjects	reported	Oral	lichen	Planus	ﬂare	up	
Lost	to	follow	up	(n=1)	
Reason:	Possible	allergic	reac?on	
Analyzed	(n=21)	
Enrollment	
Excluded	(n=2)	
•  Not	mee?ng	inclusion	criteria	(n	=1)	
•  Declined	to	par?cipate	(n=1)	
Randomized	(n=43)	
Alloca?on	
Analysis	
Analyzed	(n=15)	
 
 
From the 45 patients screened, two were excluded. One did not meet inclusion 
criteria because she had Sjogren’s Syndrome. The second subject declined to participate. 
Forty-three subjects were included in the study and randomized into two groups. 
Twenty-five participants received the active gel first then the placebo. This group was 
called the Active-Placebo (A-P). The group consisted of 7 males and 14 females with an 
average age of 61.61 ± 10.52 years. The second group of 18 subjects was called Placebo-
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Active (P-A) group because they were given placebo gel first. The P-A group consisted 
of 4 males and 11 females with an average age of 57 ± 19.01 years. During the course of 
the study, a total of seven subjects dropped out. Four were from the A-P group. One 
subject was lost to follow-up because he started to smoke again. Three subjects 
discontinued due to scheduling conflicts. In the P-A group, 3 subjects also dropped out. 
One subject was lost to follow-up because she was diagnosed with influenza. One 
subject reported a flare-up of oral lichen planus while one subject reported a possible 
allergic reaction from the placebo gel. After subtracting the drop-outs, a total of 21 
subjects in the A-P group completed the study and 15 in the P-A group (Figure 2).  
Patient Satisfaction Survey Analysis 
Figure 5 shows patient satisfaction survey results for both groups at baseline, 2 
weeks, 4 weeks, 8 weeks, and 10 weeks. The survey consisted of 5 questions. Subjects 
that used the active gel first were very satisfied with the soothing effect of the gel. This 
effect carried through use of the placebo as well. Subjects that used the placebo gel first 
were unsatisfied with the soothing effect of the gel. However, subjects reported highly 
satisfactory soothing effects of the active gel after the crossover at week 6. A statistically 
significant difference (p< 0.05) was found in the subjective measure of soothing effect at 
week 4. The paired t-test showed a statistically significant difference at week 4. 
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Figure 5 Mean of the Soothing Effect in the Mouth After Using the Dry Mouth Gel 
 
  
 
Figure 6 indicates that during use of the active gel, both groups showed less time 
required to feel relief compared to their response when using the placebo. Placebo group 
was more unsatisfied before crossover at week 4.  
 
Very unsatisfied 
Very satisfied 
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Figure	6	Mean	Time	It	Took	To	Feel	Relief	After	Using	The	Dry	Mouth	Gel	
 
 
Figure 7 indicates the A-P group voiced greater satisfaction with confidence in 
breath after use of the active gel first. The two A-P group were more satisfied than the 
two P-A groups but there was no statistically significant difference between the groups. 
 
Very unsatisfied 
Very satisfied 
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Figure 7 Mean Confidence In Breathe After Using the Dry Mouth Gel 
 
 
 
Figure 8 does not indicate a trend in the data for this variable. However, paired t-
test shows that the ability to eat at week 2 was significantly different amongst data sets 
of both the active and placebo groups.  
 
Very unsatisfied 
Very satisfied 
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Figure 8 Mean Ability to Eat Using the Dry Mouth Gel 
 
 
 
Figure 9 shows subjects report greater satisfaction with the ability to sleep 
through the night with the active gel in both groups.  
 
Very unsatisfied 
Very satisfied 
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Figure 9 Mean Ability to Sleep Through the Night After Using the Dry Mouth Gel 
 
 
 
Xerostomia Visual Analog Scale Analysis 
The following are the XVAS findings (validated questionnaire to evaluate five 
questions related to xerostomia) for both groups at baseline, 2 weeks, 4 weeks, 6 weeks, 
8 weeks, and 10 weeks. The VAS consisted of five items.  
  In figure 10 there is a trend showing that subjects that used the active gel first 
had less difficulty speaking over time compared to subjects that began with the placebo 
gel. Furthermore, once group P-A switched to the active gel, there was a trend towards 
less difficulty speaking over time.  
 
 
Very satisfied 
Very unsatisfied 
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Figure 10 Mean Difficulty in Speaking 
 
 
 
Figure 11 shows there is a trend that difficulty swallowing decreased in group P-
A after switching to the active gel. Otherwise, the two groups remained relatively similar 
for this category.  
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Figure 11 Mean Difficulty in Swallowing 
 
 
 
In figure 12 both groups reported less of a decrease in saliva in the mouth after 
using the gels. The decrease over time is significant in both groups. However, there is 
not a statistically significant difference between the groups over time.  
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Figure 12 Mean Decrease in Saliva in the Mouth 
 
 
 
In figure 13 both groups reported a decrease in dry mouth over time.  
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Figure	13	Mean	Dry	Mouth	
 
 
 
Figure 14 shows there was a non-significant decrease in dry throat reported by 
both groups throughout the entire study. Placebo group reported higher levels of dry 
throat at initial baseline (0 week) compared to the active group. Once the placebo group 
changed to active group after the crossover at week 4 they remained reporting at dry 
throat at higher levels compared to other group. 
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Figure 14 Mean Dry Throat 
 
 
Medication Consumption Analysis 
 All subjects were taking drugs with potential to cause dry mouth. Figure 15 
shows patients that produced salivary flow of <0.2 ml/min and the medications they 
were taking. For these patients, 25 were prescribed analgesic medications and 19 anti-
hypertensive medications. 
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Figure 15 Medication In Patients With Salivary Flow Rate Levels Of <0.2ml/Min 
 
 
 
Figure 16 shows patients that produced salivary flow of >0.6 ml/min and the 
medications they (n=20) were taking. This figure shows that subjects that were able to 
produce increased saliva were not prescribed any analgesics or anti-hypertensive 
medications. 
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Figure 16 Medications For Subjects With Flow >0.6 Ml/Min. 
	
 
  
TAC Analysis 
All the figures for TAC analysis were done for patients with salivary flow of 
<0.2 ml/min. Figure 17 shows that the TAC averages during the Active phase increased 
then decreased slightly by week 4 and the decrease persisted during the placebo phase, 
but no major change was found from beginning to end. Placebo-Active also increased 
initially during the active phase then decreased and no major difference was found from 
the active phase beginning point to the end. Raw values of all subjects’ (n=36) TAC are 
presented in Table 3. 
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Figure 17 Averages Of TAC Comapring P-A To A-P 
 
 
 
Table 3 TAC Averages For All Subjects In The Study 
 
 
 
In figure 18 TAC average increased prior to an increase in salivary flow. TAC 
peaked at week 2 and salivary flow peaked 2 weeks after TAC seemed to increase as the 
salivary flow increased. No significant relationship was found regarding the activity of 
the gel. 
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Figure 18 TAC Active-Placebo Averages Comapred To Salivary Flow Rate 
 
 
 
Figure 19 shows Placebo-Active TAC averages increased during the placebo 
phase and decreased during active phase. Salivary flow peaked during active phase but 
TAC levels did not change significantly from beginning to end. 
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Figure	19	Placebo-Active	TAC	Averages	Compared	To	Salivary	Flow.	
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4. DISCUSSION 
 
 
The goal of treating xerostomia is to alleviate symptoms and stimulate saliva.9, 40 
In this study population that was affected by drug induced xerostomia, topical 
application of antioxidant gel was effective in treating some symptoms. The gel 
improved salivary flow rate and patient satisfaction regarding the soothing effect of the 
gel. The descriptive results of TAC showed that there was an increase or decrease in 
TAC as the salivary flow increased or decreased. Observation of the trends associated 
with dry mouth did not reveal a relationship between VAS or PSS. The results obtained 
regarding xerogenic effects of medication, showed that anti-hypertensive and analgesic 
medications were the two dominant classes of drugs taken by patients that produced low 
salivary flow of <0.2 ml/min.  
Topical agents are abundantly available over the counter, and many xerostomic 
patients find relief of their symptoms with their use. However, a Cochrane review on 
topical therapy found no strong evidence for alleviating symptoms of dry mouth, 
indicating that most treatments are palliative and transient.64 There are several forms of 
palliative treatment. Salivary substitutes are more viscous in nature such as gels, oils, 
and mouthwashes. Salivary stimulants entails chewing gums, toothpastes, or lozenges.9 
To date, there is no gold standard available to treat xerostomia with topical agents. 
Cholinergic stimulants such as pilocarpine will improve salivary flow but have mixed 
results when it comes to improving patients’ assessment of symptoms or quality of life 
measures.65 These drugs come with a price of side effects and some patients are unable 
  
 
 
61 
to take them due their adverse drug interactions and contraindications with systemic 
diseases.66 Side effects include hypersalivation, nausea, emesis, diarrhea, hiccups, 
hyperhidrosis, cutaneous vasodilatation, bronchoconstriction, bradycardia, hypotension, 
and difficulty in visual accommodation. They are contraindicated in acute asthma attack, 
narrow-angle glaucoma, and iritis.12 
Many agents aid with short-term relief of dry mouth as was described in a study 
by Gil-Montoya et al. They evaluated the efficacy of mouthwash and oral gel consisting 
of antimicrobial proteins lactoferrin, lactoperioxidase, and lysozyme in 20 elderly 
patients during a 4-week period. The study concluded that few symptoms actually 
improved. Moreover, they found a substantial placebo effect. They also found VAS 
measurements improved in both active and placebo groups.67 Femiano et al. evaluated 
54 patients reporting drug-induced xerostomia. Subjects were randomly divided into 
three groups and were dispensed either artificial saliva, 3% citric acid, or distilled water 
as mouthwash 4 times a day for 30 days. They collected unstimulated whole saliva 
before and after therapy and answered survey questions. The study concluded that saliva 
and citric acid produced immediate stimulation (p <0.0001 after 15 min period) but it 
only persisted for an hour longer in the citric acid group. Moreover, the overall salivary 
flow rate did not show significant increase in any of the subject groups.68 On the 
contrary, Epstein et al. reported that Biotene™ was more effective than placebo.66 
An antioxidant gel appears to provide a longer lasting soothing effect. In this 
study, the soothing effect carried through the placebo intervention. Subjects who used 
the placebo gel first found the gel less satisfying until they transferred to the active 
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group. The initial improvement in the placebo group could be due to the well-known 
placebo effect. Once the subjects in the initial active group felt benefit and relief from 
the active gel intervention they started to associate the placebo gel with a benefit as 
well.69, 70 There was not a dramatic beneficial change in the A-P group compared to P-A 
group when comparing starting point and end point. In other words, both groups found 
considerably more satisfaction when using the active gel. Epstein evaluated Biotene™ 
toothpaste and rinse against Biotene Oral Balance™ gel and found the gel to be more 
soothing to patients than the other Biotene™ products although all products yielded 
positive responses from patients despite not resulting in any improvement in salivary 
output. On the other hand, the long-term 6 week improvement in soothing effect and 
salivary output in the A-P group could indicate a lingering effect of the product. 
Adherence of polyphenols to mucosal surfaces and persisting for longer time periods 
may allow the gel to function as a slow-releasing device.36 Starting a sustained redox 
cascade event that leads to an increased salivary flow. It is also possible that the placebo 
gel itself alone had some inherent antioxidant properties. Ferulic acid and phloretin were 
not utilized in the placebo, but secondary ingredients including: menthol, thyme, sage 
oil, clove flower oil, and xylitol were used. Several studies have shown that these 
ingredients carry antioxidant functions as well. 71-74 It was not possible to provide the 
placebo gel with out these ingredients since it would change the gel consistency, taste, 
and smell. Despite the similarities of the secondary ingredients, it is evident that the 
active gel increased satisfaction of patients compared to the placebo. Therefore, it can be 
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assumed that any differences are attributed to the active components, mainly phloretin 
and ferulic acid. 
Even though no statistically significant differences was found apart from the 
soothing effect in the mixed model analysis, the patient survey results showed a decrease 
of symptoms overall. These findings correlate with other studies from Table 2. From 
general observation, patients who presented with severe dry mouth did not experience 
alleviation of symptoms, but subjects who had low salivary flow were more content with 
use of the gel.  
A weakness of this study was the methodology used for saliva collection. 
Collecting only unstimulated whole saliva through the spit method could have led to 
some salivary output discrepancies. Other methods of collecting saliva include draining, 
swab, and suction. The spit method obtains saliva that is accumulating in the floor of the 
mouth while the mouth is closed. The saliva is primarily produced by the submental and 
submandibular glands producing the bulk of salivary mucins allowing for lubrication in 
the oral cavity, the protective saliva coating of oral soft tissues, and the formation of 
dental pellicle. When subjects feel the urge to swallow the saliva, they are urged to spit 
into a test tube. The method is problematic in that it may cause a stimulatory effect on 
saliva secretion and may not reflect the most reliable values. In the draining method 
unstimulated whole salivary flow is collected when the patient is in an upright position. 
The patient is then instructed to swallow and tilt their head in a forward position to move 
saliva to the front of the mouth. The patient then lets saliva drain continuously from the 
lower lip through a funnel, which directs fluid into a graduated cylinder for 15 min. The 
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remaining saliva is spat out at the end. The draining method has a higher degree of 
evaporation of saliva compared to the spitting method. This makes the spit technique a 
more applicable method in patients suffering from severely reduced salivary flow rates. 
Consensus of saliva experts appears to be that ideally both stimulated and unstimulated 
saliva should be collected especially if salivary gland injury is suspected as in Sjogren’s 
Syndrome.20 
Looking at the effect of anti-hypertensive drugs in patients with/without type 2 
diabetes mellitus (DM), Djukic et al. found that drug combinations and metoprolol 
exhibit xerogenic effects. The subject population consisted of 447 (378 hypertensive and 
60 healthy) individuals. Patients diagnosed with type 2 DM had more noticeable 
xerogenic effect of anti-hypertensive drugs.75 This finding could have played a role in 
salivary output of several individuals in this patient population who had DM and also 
took antihypertensive medications. Although not all studies concur, the literature 
suggests that polydrug therapy may increase the severity of xerostomia.20, 76 Bardow et 
al. showed that the total amount of medications taken daily and the number of xerogenic 
medications had a significant association with xerostomia.77 Another study showed that 
subjects taking more than three medications per day had higher risk of developing 
xerostomia compared to subjects taking only one medication daily.78 A systematic 
review by Villa et al. concluded that as the number of medications increases, the severity 
of xerostomia worsens. This may be due to the fact that taking additional xerogenic 
drugs potentiates the xerogenic effect of the original medication.1  
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In the present study, one subject reported a possible allergic reaction to the gel. 
She was given the placebo gel first, from which she developed contact dermatitis of the 
lips. Crusting, erythema, and eczema-like dryness appeared on the vermilion margin 
around the mouth. The participant was offered the opportunity to be allergy tested in 
order to identify any allergen found in the placebo gel. However, she decided not to be 
tested but to terminate involvement in the study as a safety precaution.  
Another patient reported flare-up of oral lichen planus. This patient was type 2 
diabetic and studies have shown that diabetic patients are more prone to developing 
several stomatological manifestations including oral lichen planus and xerostomia.79-81 
It has been reported that most diabetic patients who appear to have oral lichen planus, in 
fact are experiencing a lichenoid drug reaction to one or more of the medications 
prescribed for DM.82 
Fruits and vegetable are known to provide increased amounts of antioxidants. 
Xerostomia patients also often use over-the-counter dry mouth products that may contain 
antioxidants components in addition to lubricants. Another weakness of the study is that 
subjects’ dietary habits and gel usage of over-the-counter dry mouth products were not 
investigated and controlled, respectively, which may have affected the results as 
confounding factors.36  
TAC of blood plasma has also been correlated to age, with the 40 -60 year olds 
showing lower TAC values when compared to 18-24 and 25-39 year old populations.83 
Most of our patients were from the 40-60 year old age group. Many potential factors 
may have led to the overall inconsistent TAC levels in the study including diet and the 
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presence of oral inflammatory diseases or conditions. Even though an increase in TAC 
was observed when using the active gel, overall there was no significant difference.  
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5. CONCLUSION 
 
 
 The present study demonstrated that drug-induced xerostomia did not lead to a 
significant alteration of salivary TAC, although all active product participants 
experienced a significant surge in TAC at two weeks followed by a reduced but still 
elevated TAC at completion of the active phase. Of interest, individuals in the first 
active product group continued to have an elevated but not significant TAC level 6 
weeks later at the final completion of the 10-week study. An interesting observation was 
that TAC levels increased prior to peak salivary flow rates suggesting that the 
antioxidants may trigger a reaction resulting in increased salivary flow. This observation 
cannot currently be explained on a molecular basis. 
Patients receiving the active AO gel had improvement in the carefully selected 
and evaluated XVAS questionnaires and the Patient Satisfaction Survey. Overall, the 
VAS testing between the active and placebo groups were not statistically significant 
except for soothing effect of the gel, with paired T-test showing improved ability to eat 
at week 2 and in subjective measurement of soothing effect at week 4.   Other VAS 
survey questions also indicated an improvement of symptoms with use of the active AO 
gel, and suggest that ongoing evaluation of validity testing of VAS changes in salivary 
output should continue.  
Although the study identified large variability in the data, the antioxidant gel 
formula resulted in an increase of unstimulated whole salivary flow over the 10-week 
study period. Survey results also indicated an improvement of symptoms using the AO 
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gel. Although there were insufficient numbers to confirm significance there were strong 
indications that a surprisingly large percentage of individuals taking xerogenic 
medications experienced very low normal salivary levels or salivary hypofunction.  
Additionally those individuals with low salivary output tended to responds much more 
favorably to AO application. 
  This antioxidant gel formula showed strong potential to provide a beneficial 
outcome for patients suffering from drug-induced xerostomia. Further research should 
include large-scale clinical trials, with or without use of additional sources of AO, to 
investigate the efficacy of antioxidants in achieving and sustaining oral health.  
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